Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• HongWDongEThe past, present and future of breast cancer research in ChinaCancer Lett201435111524735750
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• GradisharWJAndersonBOBalassanianRNCCN guidelines insights breast cancer, version 1.2016J Natl Compr Canc Netw201513121475148526656517
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTGellerMLAdherence to endocrine therapy for breast cancerOncology2006711–21917344666
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMResults of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet20053659453606215639680
   PubMed Web of Science ®Google Scholar
• HershmanDLKushiLHShaoTEarly discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsJ Clin Oncol201028274120412820585090
   PubMed Web of Science ®Google Scholar
• van Herk-SukelMPvan de Poll-FranseLVVoogdACNieuwenhuijzenGACoeberghJWHeringsRMHalf of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysisBreast Cancer Res Treat2010122384385120058066
   PubMed Web of Science ®Google Scholar
• FrieseCRPiniTMLiYAdjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancerBreast Cancer Res Treat2013138393193923542957
   PubMed Web of Science ®Google Scholar
• LinJHZhangSMMansonJEPredicting adherence to tamoxifen for breast cancer adjuvant therapy and preventionCancer Prev Res (Phila)2011491360136521893499
   PubMed Web of Science ®Google Scholar
• KilicNMyrickMESchmidSMGuethUEligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2–3 years of tamoxifen in endocrine adjuvant breast cancer therapyOncology2011813–415115722041855
   PubMed Web of Science ®Google Scholar
• BarronTIConnollyRBennettKFeelyJKennedyMJEarly discontinuation of tamoxifen: a lesson for oncologistsCancer2007109583283917243168
   PubMed Web of Science ®Google Scholar
• MalekiZShariatSMokriMAtriMER-negative/PR-positive breast carcinomas or technical artifacts in immunohistochemistry?Arch Iran Med201215636636922642247
   PubMed Web of Science ®Google Scholar
• ClarkeRLiuMCBoukerKBAntiestrogen resistance in breast cancer and the role of estrogen receptor signalingOncogene200322477316733914576841
   PubMed Web of Science ®Google Scholar
• van NesJGFonteinDBHilleETQuality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side studyBreast Cancer Res Treat2012134126727622453754
   PubMed Web of Science ®Google Scholar
• MoralesLNevenPTimmermanDAcute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patientsAnticancer Drugs200415875376015494636
   PubMed Web of Science ®Google Scholar
• WangDCGuoCBPengXSuYJChenFIs therapeutic nondisclosure still possible? A study on the awareness of cancer diagnosis in ChinaSupport Care Cancer20111981191119520628766
   PubMed Web of Science ®Google Scholar
• DentSFGaspoRKissnerMPritchardKIAromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancerBreast Cancer Res Treat2011126229531021249443
   PubMed Web of Science ®Google Scholar
• GuthUMyrickMESchotzauAKilicNSchmidSMDrug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?Breast Cancer Res Treat2011129379980721750963
   PubMed Web of Science ®Google Scholar
• BriotKTubiana-HulinMBastitLKloosIRouxCEffect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) studyBreast Cancer Res Treat2010120112713420035381
   PubMed Web of Science ®Google Scholar
• HadjiPBlettnerMHarbeckNThe Patient’s Anastrozole Compliance to Therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancerAnn Oncol20132461505151223378537
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIBaumMATAC/LATTE InvestigatorsEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialLancet Oncol201011121135114121087898
   PubMed Web of Science ®Google Scholar
• RydenLHeibert ArnlindMVitolsSHoistadMAhlgrenJAromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – meta-analyses on efficacy and adverse events based on randomized clinical trialsBreast20162610611427017249
   PubMed Web of Science ®Google Scholar
• PrehnAWTopolBStewartSGlaserSLO’ConnorLWestDWDifferences in treatment patterns for localized breast carcinoma among Asian/Pacific islander womenCancer200295112268227512436431
   PubMed Web of Science ®Google Scholar
• HuiartLDell’AnielloSSuissaSUse of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancerBr J Cancer2011104101558156321522148
   PubMed Web of Science ®Google Scholar
• DittmerCRoederKHoellenFSalehinDThillMFischerDCompliance to adjuvant therapy in breast cancer patientsEur J Gynaecol Oncol201132328028221797116
   PubMed Web of Science ®Google Scholar
• MaAMBaroneJWallisAENoncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patientsAm J Surg2008196450050418809051
   PubMed Web of Science ®Google Scholar
• McCowanCShearerJDonnanPTCohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancerBr J Cancer200899111763176818985046
   PubMed Web of Science ®Google Scholar
• PartridgeAHWangPSWinerEPAvornJNonadherence to adjuvant tamoxifen therapy in women with primary breast cancerJ Clin Oncol200321460260612586795
   PubMed Web of Science ®Google Scholar
• LashTLFoxMPWestrupJLFinkAKSillimanRAAdherence to tamoxifen over the five-year courseBreast Cancer Res Treat200699221522016541307
   PubMed Web of Science ®Google Scholar
• FinkAKGurwitzJRakowskiWGuadagnoliESillimanRAPatient beliefs and tamoxifen discontinuance in older women with estrogen receptor – positive breast cancerJ Clin Oncol200422163309331515310774
   PubMed Web of Science ®Google Scholar
• CluzeCReyDHuiartLAdjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over timeAnn Oncol201223488289021788360
   PubMed Web of Science ®Google Scholar
• HenryNLEndocrine therapy toxicity: management optionsAm Soc Clin Oncol Educ Book201434e25e30
   Google Scholar
• HorneRWeinmanJPatients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illnessJ Psychosom Res199947655556710661603
   PubMed Web of Science ®Google Scholar
• WengstromYAaproMLeto di PrioloSCannonHGeorgiouVPatients’ knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European studyBreast200716546246817449249
   PubMed Web of Science ®Google Scholar
• BriestSStearnsVAdjuvant aromatase inhibitors and emerging quality-of-life considerationsExpert Rev Anticancer Ther2008811418095876
   PubMed Web of Science ®Google Scholar
• HartiganKPatient education: the cornerstone of successful oral chemotherapy treatmentClin J Oncol Nurs200376 Suppl2124
   Google Scholar